NUR 5033 Module 6 Proposal Defense Example

Ready by the First of the Month: Defending a Sickle Cell Pain Protocol Against Five Objections From the People Who Would Run It

Student Name

American College of Education

NUR5033: Advanced Nursing and Practice II

Module 6 Assignment

Instructor Name

August 9, 2027

The Proposal in One Paragraph

At the community emergency department examined across this course, which is fictional, a person arriving with a sickle cell crisis typically waits over an hour and a half for the first opioid, three times the 30 minutes national guidance allows, and longer than someone with a broken bone and similar pain. The proposal combines advance pain plans, agreed between each patient and a hematology nurse practitioner, with a triage protocol, signed by the medical director with explicit exclusions, that lets the triage nurse give the first dose from the plan or a default weight-based order once the patient is in a monitored space. Its start-up bill is roughly $12,500, with about $6,700 in running costs each year, and it will be measured against the baseline on timing, fidelity, admissions, returns, safety and equity. The question for this module is not whether the proposal is good but whether the people who must run it will agree to start it next month.

Objections One and Two: Opioid Safety and Stewardship

The first objection, likely from a physician or pharmacist, is that a standing order for opioids at triage runs against the hospital's efforts to reduce opioid prescribing. In its strongest form it says that any protocol making opioids easier to give will be used more widely than intended. The answer is that the protocol is narrow by design. It applies only to patients with a documented diagnosis of sickle cell disease, gives only the first dose, draws the dose from a plan written by a specialist or a default order reviewed by pharmacy and excludes patients with red-flag symptoms. Opioid stewardship is about giving opioids where they are the right treatment and not elsewhere, and national guidance identifies rapid opioid treatment of severe sickle cell pain as a strong recommendation (Yawn et al., 2014).

The second objection, likely from nurses, is safety: a nurse giving an opioid before a physician has seen the patient could miss a complication or cause oversedation. The concession is that the risk is real, which is why the feasibility analysis modified the protocol. The first dose is given only in a monitored space, the triage nurse screens for fever, chest pain, new neurologic signs and pregnancy before giving it, the nurse can decline and call a physician whenever the presentation does not match the plan, and sedation is scored 30 minutes later. Every naloxone administration after a protocol dose triggers a case review. The safety design is part of the proposal, not an afterthought.

Objection Three: The Drug-Seeking Concern

The third objection is rarely stated in a meeting but often felt: some patients with frequent visits are thought to be seeking drugs, and a protocol that gives them opioids faster rewards that behavior. The answer needs care. Frequent visits in sickle cell disease usually reflect severe disease rather than misuse, and the baseline data showed that the most frequent visitors waited longest, which is the opposite of what fair treatment would produce. Glassberg et al. (2013) found that the emergency providers whose attitudes toward this patient group were least favorable were less likely to redose opioids promptly when pain relief was inadequate, which is evidence that attitudes can slow care.

The proposal answers the concern with structure rather than argument. Each plan is written with the patient and a hematology specialist who knows the patient's history, so the dose and the limits are set by someone with full information rather than by a clinician meeting the patient for the first time in a crisis. If a specialist believes a patient's opioid use is a concern, that belief can be addressed in the plan, openly and with the patient, rather than through delay at the bedside. A written plan replaces suspicion with agreement, which protects both the patient and the clinician who treats them.

Objections Four and Five: Capacity and Cost

The fourth objection, from the charge nurses, is capacity: on busy nights there is no monitored space to put the patient in, so the 30-minute target cannot be met. The concession is that the target will not be met on every visit. The protocol gives the charge nurse authority to prioritize a patient with sickle cell pain for the monitored chair beside triage, and the measurement plan will track how often the lack of a monitored space causes delay, so that the department can decide whether to add a second monitored chair. Meeting the target on most visits would still be a large improvement on 5 percent.

The fifth objection, from administration, is cost and competing priorities. Set against a department budget, the start-up and running costs estimated in the feasibility analysis are small, and the potential offset from avoided admissions is much larger. The pediatric evidence on individualized plans showed a substantial fall in admissions (Krishnamurti et al., 2014), though the adult effect is uncertain, and the hematology guidelines note that most of their recommendations rest on low-certainty evidence (Brandow et al., 2020). The honest case is that the change is inexpensive, low risk and consistent with national guidance, and that its effect on admissions will be measured rather than assumed.

The Version That Starts Next Month

The full proposal takes about three months to put in place, because plans must be written with 41 patients. A smaller version can start on the first of next month. The medical director signs the triage protocol with the default weight-based order and the exclusions; pharmacy builds the default order; the clinical nurse specialist trains triage nurses in two sessions; and the hematology nurse practitioner writes plans first for the nine patients who account for more than half of all visits. From the first day, every sickle cell pain visit is covered by either a plan or the default order, and individualized plans are added for the remaining patients over the following two months.

The team will stop and review the protocol if any patient has a serious adverse event linked to a protocol dose, if naloxone is given after protocol doses more than twice in a quarter or if fidelity to the triage safety screen falls below 90 percent on the monthly audit. Stating in advance what would cause a pause is part of what makes the start acceptable to those who are cautious.

Conclusion

The proposal survives its five strongest objections, sometimes with a direct answer and sometimes with a concession built into the design. Opioid stewardship and nurse safety concerns are met by a narrow protocol with explicit exclusions, monitoring and case review. The drug-seeking concern is met by plans written in advance with a specialist and the patient. Capacity and cost concerns are acknowledged and measured rather than dismissed. A smaller version of the change can start next month, covering every visit from the first day, with stopping rules that give cautious colleagues a reason to agree. That is what it means for a proposal to be ready to run.

References

Brandow, A. M., Carroll, C. P., Creary, S., Edwards-Elliott, R., Glassberg, J., Hurley, R. W., Kutlar, A., Seisa, M., Stinson, J., Strouse, J. J., Yusuf, F., Zempsky, W., & Lang, E. (2020). American Society of Hematology 2020 guidelines for sickle cell disease: Management of acute and chronic pain. Blood Advances, 4(12), 2656-2701. https://doi.org/10.1182/bloodadvances.2020001851

Glassberg, J. A., Tanabe, P., Chow, A., Harper, K., Haywood, C., Jr., DeBaun, M. R., & Richardson, L. D. (2013). Emergency provider analgesic practices and attitudes toward patients with sickle cell disease. Annals of Emergency Medicine, 62(4), 293-302. https://doi.org/10.1016/j.annemergmed.2013.02.004

Krishnamurti, L., Smith-Packard, B., Gupta, A., Campbell, M., Gunawardena, S., & Saladino, R. (2014). Impact of individualized pain plan on the emergency management of children with sickle cell disease. Pediatric Blood & Cancer, 61(10), 1747-1753. https://doi.org/10.1002/pbc.25024

Yawn, B. P., Buchanan, G. R., Afenyi-Annan, A. N., Ballas, S. K., Hassell, K. L., James, A. H., Jordan, L., Lanzkron, S. M., Lottenberg, R., Savage, W. J., Tanabe, P. J., Ware, R. E., Murad, M. H., Goldsmith, J. C., Ortiz, E., Fulwood, R., Horton, A., & John-Sowah, J. (2014). Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members. JAMA, 312(10), 1033-1048. https://doi.org/10.1001/jama.2014.10517